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Abstract
Background: Trans-splicing strategies for mRNA repair involve engineered transcripts designed to anneal target mRNAs in
order to interfere with their natural splicing, giving rise to mRNA chimeras where endogenous mutated exons have been
replaced by exogenous replacement sequences. A number of trans-splicing molecules have already been proposed for
replacing either the 59 or the 39 part of transcripts to be repaired. Here, we show the feasibility of RNA surgery by using a
double trans-splicing approach allowing the specific substitution of a given mutated exon.
Methodology/Principal Findings: As a target we used a minigene encoding a fragment of the mdx dystrophin gene
enclosing the mutated exon (exon 23). This minigene was cotransfected with a variety of exon exchange constructions,
differing in their annealing domains. We obtained accurate and efficient replacement of exon 23 in the mRNA target.
Adding up a downstream intronic splice enhancer DISE in the exon exchange molecule enhanced drastically its efficiency up
to 25–45% of repair depending on the construction in use.
Conclusions/Significance: These results demonstrate the possibility to fix up mutated exons, refurbish deleted exons and
introduce protein motifs, while keeping natural untranslated sequences, which are essential for mRNA stability and
translation regulation. Conversely to the well-known exon skipping, exon exchange has the advantage to be compatible
with almost any type of mutations and more generally to a wide range of genetic conditions. In particular, it allows
addressing disorders caused by dominant mutations.
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Introduction
Mutations in the dystrophin gene cause Duchenne muscular
dystrophy (DMD), the most common severe childhood muscular
pathology. Recently, exon skipping strategies have proven to be
efficacious in restoring functional dystrophin expression in models
of muscular dystrophy including the mdx mouse, the GRMD dog
and muscle stem cells from DMD patients and in DMD patients
by local intramuscular injection [1–6]. Indeed, the modular
structure of the dystrophin, with its central rod-domain made of 24
spectrin-like repeats, tolerates large internal deletions [7–8].
However, exon skipping strategies only concern patients for whom
forced splicing would generate a shorter but still functional
protein. Many pathological situations escape this prerequisite.
Fortunately, RNA repair strategies based on trans-splicing
approaches could overcome this problem. Trans-splicing ap-
proaches or Spliceosome-mediated RNA trans-splicing (SMaRT;
Intronn proprietary technology) [9] use RNA molecules that
interfere with the natural splicing of targeted mRNAs in order to
repair mutated gene products. Mostly, trans-splicing studies have
developed therapeutic RNAs replacing the 39 part of the transcript
to be repaired. They have been applied to correct a number of
mutations using minigenes or endogenous transcripts in genetic
disease context like hemophilia A [10], spinal muscular atrophy
[11], X-linked immunodeficiency [12] and cystic fibrosis where the
widespread mutation CFTRDF508 was replaced efficiently in vivo
by the normal sequence via a trans-splicing reaction [13]. On the
other hand, only a few attempts for 59 replacement have been
reported to be successfull on minigenes [14–15]. Conversely to
conventional gene therapy, trans-splicing approaches could
address disorders caused by dominant mutations, while preserving
levels and tissue specificity.
Exon exchange using double trans-splicing at both sides of the
targeted exon has never been achieved but its interest has already
been underlined [16–18]. It would have the further advantages of
minimizing exogenous material as well as preserving full
regulatory elements potentially present in 59 and/or 39 untrans-
lated domains of the rescued mRNA.
The study presented here relates the optimization of exon
exchange (ExChange) constructs designed for rescuing mutated
mRNAs from very large genes such as the dystrophin gene. The
murine model for dystrophin mutations, the mdx mouse, carries a
nonsense mutation in exon 23 of the dystrophin gene [19]. In
order to test the proof of concept that double trans-splicing was
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genomic fragment containing the mdx mutation; beginning at exon
22 and ending after the exon 24 under the control of a constitutive
promoter. This minigene was cotransfected with a variety of exon
exchange constructions, differing in their annealing domains. We
show here for the first time that ExChange is possible. Indeed, we
show accurate and efficient replacement of exon 23 in the target
mRNA. Adding up a downstream intronic splice enhancer DISE
in the ExChange molecule improved its efficiency up to 25–45%
of repair. This new approach opens diverse avenues of modifying
RNA sequences ‘‘a ` la carte’’ by exchanging mutated exons,
introducing new exons or even correct duplication mutations.
Results
Design of trans-splicing molecules
In ExChange molecules, the replacing exon is flanked by
artificial intronic sequences with strong acceptor and donor splice
sites, which are connected to antisense sequences designed to
anneal the target mRNA. Annealing is crucial to permit the trans-
splicing reaction, although it is not enough. Ideally, the site of
binding must disturb the definition of the targeted exon in the
parental pre-messenger while enhancing cross-splicing in between
the two independent mRNAs. In the case of ExChange, there are
more constraints since two trans-splicing reactions must be
synchronized at both edges of the targeted exon.
The murine model for dystrophin mutations, the mdx mouse,
carries a nonsense mutation in exon 23 (E23
m) of the dystrophin
gene. In order to locate the best site of annealing in intron 22,
upstream the mutated exon, we designed first three trans-splicing
(TS) molecules for 39 replacement by a single trans-splicing event,
only differing in their binding domains (Fig. 1A). Antisense
sequences of 150 nucleotides (AS1, AS2 and AS3) were chosen to
match either to the 59 end, the middle or the 39 end of intron 22.
The idea was to test whether getting the TS molecule close to its
target, 59 donor splice site (59SS) of intron 22, or on the contrary,
masking the 39 acceptor splice site (39SS), would facilitate trans-
splicing. In the three constructions, the artificial intron included a
spacer sequence [20], a strong conserved yeast branch point
sequence (BP), a polypyrimidine tract (PPT) and a canonical 39
acceptor splice site (39SS) [21]. To facilitate the readout of
subsequent exon exchange experiments, we also decided to
employ exon 24 (E24) in the TS molecule instead of the normal
version of exon 23 (E23). Indeed, E24 is smaller than E23 (114
versus 213bp) allowing unequivocal distinction by RT-PCR of
repaired mRNA (E22-E24-E24) from non-repaired parental
transcripts (E22-E23
m-E24). As control, we used a trans-splicing
molecule with no binding domain (AS-).
To facilitate the analysis of dystrophin splicing in tissue culture,
we created a dystrophin minigene made of a murine genomic
fragment of 3993bp comprising E22 to E24 with full-length
natural introns. Cis- and single trans-splicing patterns are
illustrated in Figure 1B. An RT-PCR strategy was designed to
detect specifically RNA resulting from cis- and trans-splicing
events by using a forward primer E22-F (arrow A in Fig. 1B)
specific for E22, and a reverse primer pSMD2-R1 (arrow B)
specific for a sequence upstream the polyA signal in the dystrophin
minigene and TS molecules. Importantly, these primers also
allowed us to discriminate E22-E24 amplicons resulting from
either trans-splicing or exon skipping.
Single trans-splicing approach
Dystrophin minigene and TS plasmids were cotransfected in the
mouse embryonic fibroblast NIH3T3 cell-line. Cells were
harvested 72 h after transfection, and total RNA was isolated.
Cis- and trans-spliced RNA patterns were assessed by RT-PCR.
Samples that received only the mutation-bearing dystrophin
minigene displayed a single 633bp amplicon corresponding to
the cis-spliced transcript E22-E23
m-E24 (lane 1, Ctrl in Fig. 1C).
Also, cDNAs from cells transfected with both dystrophin minigene
and trans-splicing constructs (AS2-E24) gave no PCR products
when reverse transcription was omitted (lane 7, RT- AS2),
ensuring us about the specificity of our assay. In the presence of
U7-SD23-BP22 (lane 2, U7) plasmids described to induce E23
skipping [1], a predominant 420bp band corresponding to E22-
E24 transcript from cis-splicing was detected.
In samples that received dystrophin minigene and TS plasmids
(lanes 4, 5 and 6 in Fig. 1C), a product of 304bp was generated,
corresponding specifically to the trans-spliced E22-E24 variant as
shown in Figure 1D by the sequence of E22-E24 junction, and not
to an exon skipping product as it was obtained with U7. In the
presence of either AS1-E24 (lane 4) or AS2-E24 (lane 5), the E22-
E23
m-E24 amplicon corresponding to the parental dystrophin
transcript had significantly decreased thus confirming that trans-
splicing efficacies were elevated. Efficacies seem so high that the
parental template transcript has almost disappeared. We cannot
exclude that this unprecedented trans-splicing efficiency was
enlarged by a PCR bias benefiting the small trans-spliced
amplicons rather than the non-repaired template. As well, total
yields (cumulated band intensities of parental and repaired
amplicons) are not the same in all lanes, while we used comparable
amounts of minigene templates for all transfections. AS1-E24 and
AS2-E24 molecules (lanes 4 and 5) were more efficient than AS3-
E24 (lane 6), and variations could not be attributed to higher levels
of expression of these constructs as shown in Fig. S1B.
Importantly, trans-splicing did not occur when AS was removed
(lane 3, AS-) from TS constructs demonstrating that this reaction
required close interaction in between the two strands of mRNA to
combine. The AS3-E24 TS molecule (lane 6) appeared to be less
efficient. Surprisingly, extending AS3 in order to cover the 39
acceptor site of E23
m did not improve the trans-splicing reaction
(not shown). These experiments show that trans-splicing could not
be induced without AS sequences, although aligning the two
mRNAs is not sufficient.
Double trans-splicing approach: ExChange
To test the possibility of mRNA repair by ExChange, we
developed several ExChange (ExCh) molecules AS-E24-AS’ based
on the efficient TS molecules mentioned above, modified to bind
both intron 22 and intron 23 of the dystrophin minigene (Fig. 2A).
The ExCh molecules contained the same elements as previously
described in AS1-E24 and AS2-E24 TS molecules followed by a 59
donor splice site (59SS) [15] and a second 150 nt antisense
targeting intron 23. Five antisense sequences, AS5 to AS8, were
selected within intron 23, which spans over 2607bp. As described
before, ExCh constructs and dystrophin minigene were cotrans-
fected in NIH3T3 cell-line. Cells were harvested 72 h after
transfection, and total RNA was extracted. To detect specifically
RNA resulting from cis-splicing and/or exon exchange events, we
used a forward primer E22-F (arrow A in Fig. 2A–B) specific of
E22, and a reverse primer pSMD2-R5 (arrow C) specific of a
sequence only present in the dystrophin minigene upstream its
polyA signal. Targeting of AS-E24-AS’ in the dystrophin minigene
pre-mRNA is illustrated in Figure 2A and expected sizes of the
various amplification products shown in Figure 2B.
A RT-PCR product of 408bp was detected in samples
transfected with AS2-E24-AS’ plasmids (lanes 8–13, Fig. 2C).
Direct sequencing confirmed that this product corresponded to the
Exon Replacement
PLoS ONE | www.plosone.org 2 May 2010 | Volume 5 | Issue 5 | e10894Figure 1. Trans-splicing strategy for 39 replacement. (A) The murine dystrophin minigene consists of exons 22 to 24 (boxes E22 to E24) with
natural introns (lines). The splice sequences are illustrated by black balls: 59 splice sites (59SS), branching points (BP), polypyrimidine tracts (PPT) and
39 acceptor sites (39SS). The cross represents the nonsense mdx mutation in E23. The trans-splicing (TS) molecule AS-E24 comprises a 150 nt antisense
sequence (AS) complementary to intron 22 as well as a spacer, a strong conserved yeast branch point sequence, a polypyrimidine tract, a 39 acceptor
site and E24. The sequence of the spacer, BP, PPT and 39SS is given with the BP, PPT and 39SS in bold and illustrated by black balls. The E24 sequence
Exon Replacement
PLoS ONE | www.plosone.org 3 May 2010 | Volume 5 | Issue 5 | e10894exchanged mRNA variant E22-E24-E24 (Fig. 2D). This product
was absent when one of the two antisense was lacking (lanes 3 and
4, AS1 and AS2), showing that co-targeting of intron 22 and
intron 23 is crucial for ExChange. Among the antisense
combinations we tried, levels of the 408bp band were stronger
with AS2-E24-2XAS4 (lane 11), -AS7 (lane 12) and -AS8 (lane 13).
Interestingly, the AS2-E24-2XAS4 molecule, which carried two
AS4, was more efficient than its single AS4 counterpart (lane 5). In
AS2-E24-AS7 sample (lane 12), an additional band of 294bp was
detected corresponding to E22-E24 transcript generated by exon
23 skipping (see lane 1, U7). This was not surprising considering
that AS7 bound the 59 donor splice site of intron 23 and would
mask its recognition by the spliceosome. It is likely that AS4, AS7
and AS8 brought ExCh molecules closer to E23 than AS5 and
AS6 suggesting that a tight framing of the target exon is essential
for efficient ExChange.
Optimization of ExChange efficacy by adding up intronic
splice enhancers
In order to improve the ExChange reaction, the G-rich intronic
splice enhancer (ISE) from the human GH-1 gene (GeneID: 2688)
was added upstream the 39 acceptor site of AS2-E24-AS4 and
AS2-E24-AS8 [22] and the DISE sequence from the rat FGFR2
gene (GeneID: 25022) downstream the 59 donor site [14], [23]
(Fig. 3A). As shown in Figure 3B, RT-PCR analysis revealed that
insertion of the DISE sequence in AS2-E24-AS4 and AS2-E24-
AS8 molecules (lanes 8 and 12) increased significantly the 408bp
band corresponding to the E22-E24-E24 mRNA variant, while
addition of ISE sequence (lanes 7 and 11) did not enhance the
ExChange efficacy. As expected, no ExChange was observed with
control vectors lacking the downstream AS’: AS2-E24, AS2-ISE-
E24 and AS2-E24-DISE (lanes 3, 4 and 5). Figure 4 shows the
numbers of parental (PCR1) and exchanged (PCR2) transcripts
obtained by absolute quantitative RT-PCR (panel C) and
corresponding ExChange efficacy of various vectors (panel D)
was evaluated by calculating the ratio between levels obtained for
repaired transcripts (PCR2) and whole dystrophin minigene
transcripts (PCR1+PCR2). The AS2-DISE-E24-AS4 molecule
allowed obtaining 45% of exon exchange. Its efficacy was
improved by about 9-folds when compared to its counterpart
AS2-E24-AS4 lacking the DISE motif. Interestingly, introduction
of two redundant downstream AS’ (here AS4) improved
ExChange efficacy, which was about 30%. However, AS2-E24-
DISE-2XAS4 was not more efficient than AS2-DISE-E24-AS4
(data not shown). Accordingly to the results obtained with AS2-
E24-AS8 (lanes 10–13 in Fig. S2A), it is likely that highest efficacy
of DISE and 2XAS4 did not resulted from transcriptional over
activity of subsequent constructs.
We next performed a dosing study of the best ExCh molecule
AS2-E24-DISE-AS4 in the cotransfection experiments (Fig. 5),
maintaining constant the amount of dystrophin minigene while
increasing the amount of the ExCh molecule. Although we used
comparable amounts of minigene plasmid in all transfections,
absolute quantitative RT-PCR on subsequent samples showed
some discrepancies in transcript levels as shown in Figure 5B
(PCR1+PCR2). Therefore, analysis on agarose gel was only used
to confirm the absence of unexpected PCR products (Fig. 5A),
while ExChange efficacy was evaluated by absolute quantitative
RT-PCR by calculating the ratio between levels obtained for
repaired transcripts (PCR2) and whole dystrophin minigene
transcripts (PCR1+PCR2) (Fig. 5C). ExChange efficiency im-
proved with the amount of ExCh molecule in a quasi linear
manner to reach 50% of repair with one dystrophin minigene
(250 ng) for three ExCh molecules (750 ng) encoding plasmids.
Exon 23 repair by exon replacement
Having identified the best antisense targets within introns 22
and 23 of the dystrophin gene, and customized flanking acceptor
and donor splice sites of the ExChange molecule, we settled on a
new ExChange molecule designed to replace the mutated mdx
exon 23 by its wild-type version (Fig. 6A). Since both parental and
repaired minigene transcripts gave rise to similar RT-PCR
products (507bp) with primer E22-F and pSMD2-R5 (arrows A
and C in Fig. 6B), we included a HindIII restriction site into the
wild type E23. The 507bp PCR-product obtained in samples
transfected with AS2-E23-DISE-AS4 plasmid (lane 2 in Fig. 6C,
E23) was cloned into pCRH-2.1-TOPOH plasmid. Thirty clones
were obtained which were analyzed by EcoRI restriction for the
presence of E22-E23-E24 insert and by HindIII restriction to
substantiate the repaired amplicon. Among these 30 clones, 21
contained an E22-E23-E24 insert. Among them, 5 displayed the
HindIII site, the attribute of the repaired dystrophin minigene
product, meaning that about 25% of the minigene transcripts were
repaired (Fig. 6D and Fig. S3). Wild-type exon 23 exchange in
these clones was confirmed by direct sequencing.
Discussion
This study demonstrates the possibility of rescuing mutated
transcripts by specifically replacing the mutated exon by its normal
version during the splicing reaction. We relate here the
optimization and add-ons to classical trans-splicing molecules (39
replacement) required for efficient exon exchange (ExChange:
concomitant 39 and 59 trans-splicing reactions). To achieve this
goal, we set up an experimental model to detect both repaired and
non-repaired transcripts in the same detection system, allowing
accurate estimation of mRNA repair. The ExChange efficiency
reached a level of 45% (when using exon 24 as ExChange
reporter) and 25% (when using wild type exon 23) of repaired
transcripts with the ExCh molecule containing the DISE motive in
our cotransfection assay with dystrophin minigene as target.
In order to show that the repair occurred at mRNA level by
double trans-splicing and not by plasmid recombination, two
independent mutations were included in the pSMD2-AS2-E24-
DISE-AS4 construct. First, the CMV promoter was deleted to
prevent expression of the AS2-E24-DISE-AS4 ExCh molecule.
Second, the 59 splice site GT of the AS2-E24-DISE-AS4 molecule
was mutated to CT to create the splicing-deficient ExChange
molecule AS2-E24-DISE-AS4-D59SS. Absence of significant
from minigene (white box) and TS molecule (black box) are identical, only the downstream sequence differs in length. TS constructs were made with
three different antisense sequences, AS1 to AS3. Arrows indicate the positions of the forward A and reverse B PCR primers in the minigene and the TS
molecule. (B) Expected transcripts generated by cis-splicing (E23 inclusion and skipping) and trans-splicing, and the predicted sizes of the
corresponding PCR amplification products detected using the RT-PCR strategy illustrated in (A). (C) RT-PCR analysis using PCR primers A and B of
NIH3T3 cells cotransfected with dystrophin minigene and constructions pSMD2 (Ctrl), pSMD2-U7-SD23-BP22 (U7), pSMD2-E24 (AS-), pSMD2-AS1-E24
(AS1), pSMD2-AS2-E24 (AS2) and pSMD2-AS3-E24 (AS3). RT- AS2: samples containing dystrophin minigene and pSMD2-AS2-E24 without reverse
transcription; H2O: PCR negative control. Representative results from three independent transfection experiments. (D) An exact E22-E24 junction was
confirmed by sequencing of the 304bp product.
doi:10.1371/journal.pone.0010894.g001
Exon Replacement
PLoS ONE | www.plosone.org 4 May 2010 | Volume 5 | Issue 5 | e10894Figure 2. Exon replacement approach on dystrophin minigene transcripts. (A) The exon exchange molecule (ExCh) AS-E24-AS’ comprises
the same elements as the TS molecule (see Fig. 1A) followed by a 59 donor splice site (59SS) and a second antisense sequence (AS’) of 150 nt
complementary to intron 23. The sequence of 59SS is given in bold and is illustrated by a black ball. ExCh constructs were made with five different AS’
antisense sequences, AS4 to AS8. Arrows indicate the positions of the forward A and reverse C PCR primers in the minigene. (B) Expected transcripts
generated by cis-splicing (E23 inclusion and skipping) and exon exchange, and predicted sizes of the corresponding PCR amplification products
detected using the RT-PCR strategy illustrated in (A). (C) RT-PCR analysis using primers A and C of NIH3T3 cells cotransfected with dystrophin
minigene and constructions pSMD2 (Ctrl), pSMD2-U7-SD23-BP22 (U7), the TS constructions pSMD2-AS1-E24 (AS1), pSMD2-AS2-E24 (AS2) and ExCh
molecules pSMD2-AS-E24-AS’ containing AS1 or AS2 and AS4 to AS8. AS2-2XAS4, ExCh plasmid pSMD2-AS2-E24-2XAS4 containing two AS4 copies;
Exon Replacement
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cotransfected cells with dystrophin minigene and pSMD2-AS2-
E24-DISE-AS4. In the three conditions, we were not able to detect
any band corresponding to the repaired minigene product by RT-
PCR (Fig. S4), thus confirming that ExChange indeed required a
fully functional ExChange mRNA molecule, and did not occur at
the level of plasmid-DNA recombination.
Importantly, we never found abnormal or non-expected end
products, suggesting that chosen annealing sequences did not
bind to cryptic splicing sites nor obstruct slicing events in the
target mRNA. This is likely due to the use of long antisense
sequences (150 nt) [24], which were not chosen in the definition
motives of targeted exons. In actual fact it is impossible to state
that there is no non-specific trans-splicing event. In our
experiments, removing one of the two antisense domains disabled
ExChange demonstrating that annealing with the target was
crucial to achieve detectable trans-splicing reactions. Still, one
might hypothesize that ‘‘off targets’’ might trigger unexpected
trans-splicing reactions in the presence of the antisense domains
in the final construct. Finally, we have carried out the classical
experiment to assess non-specific trans-splicing by using co-
transfection with an irrelevant target gene, in this case an ACTA1
exogenous gene. No non-specific trans-splicing events were
detected (data not shown).
The trans-splicing technology uses a trans-splicing molecule
that ‘‘tricks’’ the spliceosome into using it as a substrate for
splicing. In the ExChange approach, the game is more ‘‘tricky’’
since the spliceosome must carry out a double trans-splicing
between the pre-messenger transcript and the ExCh molecule.
After having tested various combinations of antisense sequences,
we were surprised to realize that the dogmas: i) blocking
endogenous splicing signals on the nascent pre-mRNA transcript
via base-pairing or ii) on the contrary, bringing the replacing
exon closer to endogenous splice site to be joined, did not
produce the best results. Our best antisense for the first trans-
splicing (39 replacement) matched with the middle of the first
intron while the second one (59 replacement) was better when
located close to the 39 end of the exon to be replaced. Postulating
that length of the ExCh molecule is critical for its efficiency,
would explain the necessity of a close framing of the exon to be
replaced. Moreover, the spacers are certainly important elements
of the ExChange molecule, and it may be of interest to study the
influence of their length and composition on ExChange efficacy.
In the case of 59 replacement, the spacer element can be removed
without decreasing efficacy of trans-splicing constructs [15].
Conversely, in 39 replacement, the spacer sequence is crucial
since it contains intronic consensus sequences required for the
recruitment of auxiliary factors involved in the acceptor site
recognition and exon processing. For ExChange, ideally, both 59
and 39 reactions need to be synchronized, thus requiring that the
two antisense sequences concomitantly anneal the same target
mRNA molecule. In this case, it is likely that the spacer length
must fit conformational constraints dictated by the distance
between the two antisense target sequences. On the other hand,
ExChange could also arise by means of two independent target
mRNAs, which would be involved sequentially. This requires
retaining the first trans-spliced intermediate in the nucleus, so
that the second reaction might take place with a different mRNA
H20: PCR negative control. Representative results from two independent transfection experiments. (D) Accurate E22-E24 and E24-E24 junctions were
confirmed by sequencing of the 408bp product.
doi:10.1371/journal.pone.0010894.g002
Figure 3. Effect of intronic splice enhancer sequences on exon replacement efficiency. (A) Exon exchange molecules AS-E24-AS’ with
intronic splice enhancers ISE or DISE sequences. (B) RT-PCR analysis using primers A and C of NIH3T3 cells cotransfected with dystrophin minigene
and constructs pSMD2 (Ctrl), pSMD2-U7-SD23-BP22 (U7) and the following ExCh plasmids with AS4 or AS8: pSMD2-AS2-E24-AS’ (-), pSMD2-AS2-ISE-
E24-AS’ (ISE), pSMD2-AS2-E24-DISE-AS’ (DISE) and pSMD2-AS2-E24-2XAS’ (2XAS’). H20: PCR negative control.
doi:10.1371/journal.pone.0010894.g003
Exon Replacement
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compartment could be achieved by introducing intronic elements
which could bind elements of the splicing machinery, such as
DISE motives, thus signaling that splicing is not yet achieved. In
such a view, length and composition of the spacers might be
crucial for the persistence of the intermediate ExChange mRNA
chimera.
As a RNA repair strategy, the ExChange approach will
produce the corrected protein where it is naturally expressed. It
has the further advantage over other RNA surgery strategies of
correcting precisely the sequence defect without altering the rest
of the messenger sequence (i.e. the open reading frame and
untranslated regions). Hence, the regulatory sequences present in
59 and 39 UTRs are preserved, something which never happens
in classical gene therapy where cDNAs are amputated of their
non-coding sequences. These regions are now known to be
essential for mRNA stability and translation regulation; in
particular, they are targets for miRNAs which play important
role in a variety of diseases [25]. Furthermore, ExChange strategy
may allow for multiple isoforms to be repaired. In particular, this
new technology could allow therapeutic solution for genes as
complex as the dystrophin gene with a variety of mutations and
multiple isoforms.
To conclude, tools and rules provided by this study open new
avenues in the field of investigation of trans-splicing. In addition,
the ExChange strategy allows a sort of surgery of the mRNA
molecule for therapeutic purpose (genetic rescue) as well as for
basic research (protein chimeras).
Materials and Methods
Plasmids constructions
The murine dystrophin minigene target (3993bp) comprising
exons E22, E23, and E24 and the natural E23 flanking intronic
sequences was constructed by PCR amplification from mdx
genomic DNA and subcloned in pSMD2 [26] into KpnI site.
An ATG in Kozak ACCACCATGG context and a STOP codon
were introduced at both sides of the minigene. For the TS and
ExCh molecules, E24 (114bp) was amplified from the dystrophin
minigene whereas E23 (213bp) from normal murine dystrophin
cDNA. The E23 lysine codon (nucleotide +196, where nucleotide
+1 is the first E23 nucleotide) was transformed from AAA to AAG
creating a HindIII restriction site. The different domains of the TS
and ExCh molecules detailed in Results section were constructed
by PCR and subcloned in pSMD2 into HindIII and EcoRI
between the CMV promoter and the polyA signal. Antisense
sequences AS bind to dystrophin intron 22: AS1 targets
nucleotides 2763 to 2614; AS2, 2463 to 2314; AS3 2159 to
210; AS3bis 2159 to +5 (where nucleotide +1 is the first E23
nucleotide). The second antisense domains AS’ bind to dystrophin
intron 23: AS4, +1801 to +1950; AS5, +2101 to +2250; AS6,
+2401 to +2550; AS7, 25t o+145; AS8, +151 to +300 (where
nucleotide +1 is the first nucleotide of intron 23). All expression
cassettes are under the control of the strong CMV promoter and a
polyA signal. The pool of E22-E23-E24 parental and repaired
amplicons were cloned into the pCRH-2.1-TOPOH. All the
constructs were verified by sequencing.
Figure 4. Efficiency of dystrophin exon exchange induced by AS4 containing ExCh molecules. (A) Expected amplicons from PCR1 with
E23-F & E23-R primers and (B) from PCR2 with E24-F & E24-R primers. (C) Histogram showing numbers of parental and exchanged transcripts
evaluated by absolute quantitative real-time RT-PCR. PCR1 corresponds to the parental transcripts whereas PCR2 to the repaired transcripts.
PCR1+PCR2 corresponds to the totality of the dystrophin minigene transcripts. (D) ExChange efficiency estimated by calculating the ratio between
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Mouse embryonic fibroblast NIH3T3 cells (ATCC) were
maintained in DMEM (Invitrogen) supplemented with 10% heat-
inactivated FBS (Invitrogen), 100 units/ml penicillin, and 100 mg/ml
streptomycin. For transfections, cells were grown to 70% confluence
in 12-well plates and exposed to the DNA/Lipofectamine 2000
reagent (Invitrogen) complex for 5 h in DMEM before being
returned to normal culture medium. Typically, 250 ng of dystrophin
minigene and 750 ng of TS or ExCh molecules DNA were used in
each transfection except for the dosing study where 250 ng of
dystrophin minigene were cotransfected with 100, 200, 400 and
750 ng of pSMD2-AS2-E24-DISE-AS4 completed with pSMD2
plasmid to reach a total amount of 1 mg per point. Cells were
routinely analyzed 72 h after transfection.
RT-PCR analysis
Total RNA was isolated from transfected cells by using RNAeasy
extraction kit (Qiagen). Reverse transcription was performed on
200 ng of RNA by using the Superscript II (Invitrogen) and the
reverse primer pSMD2-R1 (see below) at 10 min at 25uC, 50 min at
42uC ,a n daf i n a ls t e po f5m i na t9 5 uC. To detect non-repaired and
repaired dystrophin transcripts, reverse transcribed RNA was
amplified by PCR under the following conditions: 95uC for 5 min,
30 cycles of30 sat 95uC, 1 min at 56uC,45 sto1 minat72uC, and a
final step of 7 min at 72uC.
The sequences of the primers were as followed: E22-F
GACACTTTACCACCAATGCGC (Primer A on Fig. 1A–B
and 2A–B), pSMD2-R1 CTTTCTGATAGGCAGCCTGC
(Primer B on Fig. 1A–B) and pSMD2-R5 CTCACCCT-
GAAGTTCTCAGG (Primer C on Fig. 2A–B). RT-PCR products
were separated by electrophoresis in 2% agarose gels with
ethidium bromide and sequenced.
Quantitative real-time RT-PCR
mRNA levels were measured by absolute quantitative real-time
RT-PCR method using Absolute SYBR Green Rox Mix (Thermo
scientific). Two positive control dystrophin cDNA fragments, E22-
E23-E24 and E22-E24-E24, were cloned into the pCRH-2.1-
TOPOH. As a reference samples, those plasmids were 10-fold
serially diluted (from 10
7 to 10
3 copies) and used to generate
standard curves. Real-time PCR was performed and analyzed on a
DNA Engine Opticon 2 (Bio-Rad). In each experiment, duplicates
of standard dilution series of control plasmids and first strand
cDNA generated by the Superscript II (Invitrogen) and the reverse
primer pSMD2-R1 from 200 ng of total RNA were amplified by
specific primers. Primers for E23, E23-F AGATGGCCAA-
GAAAGCACC and E23-R CTTTCCACCAACTGGGAGG,
were used to measure non-repaired dystrophin transcript; and
primers for E24-E24 junction, E24-F TGAAAAAACAGCT-
CAAACAATGC and E24-R AGCATCCCCCAGGGCAGGC,
Figure 5. Dosing study of AS2-E24-DISE-AS4 molecule. (A) RT-PCR analysis using primers A and C of NIH3T3 cells cotransfected with 250 ng of
dystrophin minigene and 100, 200, 400 and 750 ng of pSMD2-AS2-E24-DISE-AS4 plasmids. (B) Histogram showing numbers of parental and
exchanged transcripts evaluated by absolute quantitative real-time RT-PCR illustrated in Fig. 4A. PCR1 corresponds to the parental transcripts
whereas PCR2 to the repaired transcripts. PCR1+PCR2 corresponds to the totality of the dystrophin minigene transcripts. (C) ExChange efficiency of
the dosing study estimated by calculating the ratio between levels obtained for repaired transcripts (PCR2) and whole dystrophin minigene
transcripts (PCR1+PCR2). Representative results from two independent transfection experiments.
doi:10.1371/journal.pone.0010894.g005
Exon Replacement
PLoS ONE | www.plosone.org 8 May 2010 | Volume 5 | Issue 5 | e10894for the repaired transcript. ExChange efficiency was estimated by
calculating the ratio between levels obtained for repaired
transcripts (E24-F & E24-R) and whole dystrophin minigene
transcripts, approximated by summing levels of non-repaired
transcripts (E23-F & E23-R) plus the repaired subset (E24-F &
E24-R).
Supporting Information
Figure S1 Expression levels of ExChange molecules. Expression
levels of ExChange molecules were estimated by subtracting the
number of minigene transcripts, estimated by quantitative PCR
with A/D primers (E22-F & E22-R) to the number of E24 copies,
Figure 6. Exon 23 correction by exon replacement. (A) The ExCh AS2-E23-DISE-AS4 molecule comprises the same elements as AS2-E24-DISE-
AS4, except E23 instead of E24. E23 is the wild-type murine dystrophin E23 carrying a HindIII restriction site absent in the mdx minigene E23. (B)
Expected transcripts generated by cis-splicing and E23 exchange, and predicted size of the corresponding RT-PCR products using primers A and C. (C)
RT-PCR analysis using primers A and C of NIH3T3 cells cotransfected with dystrophin minigene and constructions pSMD2 (Ctrl) and ExCh plasmid
pSMD2-AS2-E23-DISE-AS4; H20: PCR negative control. Representative results from two independent transfection experiments. (D) Cloning results of
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ExCh copy number=(E/F)2(A/D). mRNA levels were measured
by absolute quantitative real-time RT-PCR methods as described
previously using pCRA ˆH-2.1-TOPOA ˆH-E22-E23-E24 as reference
sample and primers E22-F, E22-R CCGAGTCTCTCCTCCAT-
TATTTC, E24-F2 CACATAAAAACCTTACAGAAATG and
E24-R2 CTGCATTGTTTGAGCTGTTTTTTC. (A) Expected
transcripts and the anticipated PCR amplifications with A/D and
E/F primers. (B) Trans-splicing strategy for 39 replacement. RT-
PCR analysis using PCR primers A and B of NIH3T3 cells
cotransfected with dystrophin minigene and constructions pSMD2
(Ctrl), pSMD2-U7-SD23-BP22 (U7), pSMD2-E24 (AS-), pSMD2-
AS1-E24 (AS1), pSMD2-AS2-E24 (AS2) and pSMD2-AS3-E24
(AS3). RT- AS2: samples containing dystrophin minigene and
pSMD2-AS2-E24 without reverse transcription; H2O: PCR
negative control. Histogram shows the number of TS molecules
expressed for 100 copies of dystrophin minigene transcripts. AS1-
E24 and AS2-E24 molecules (lanes 4 and 5) are the most efficient.
AS3-E24 construct (lane 6) was highly expressed but promoted
lower levels of trans-splicing. (C) Exon replacement approach on
dystrophin minigene transcripts. RT-PCR analysis using primers
A and C of NIH3T3 cells cotransfected with dystrophin minigene
and constructions pSMD2 (Ctrl), pSMD2-U7-SD23-BP22 (U7),
the TS constructions pSMD2-AS1-E24 (AS1), pSMD2-AS2-E24
(AS2) and ExCh molecules pSMD2-AS-E24-AS’ containing AS1
or AS2 and AS4 to AS8. AS2-2XAS4, ExCh plasmid pSMD2-
AS2-E24-2XAS4 containing two AS4 copies; H20: PCR negative
control. Histogram shows the number of ExCh molecules
expressed for 100 copies of dystrophin minigene transcripts.
AS2-E24-2XAS4 construct (lane 11) is not highly expressed but is
the most efficient molecule in the ExChange experiments.
Found at: doi:10.1371/journal.pone.0010894.s001 (5.95 MB TIF)
Figure S2 Expression levels of ExChange molecules. Expression
levels of ExChange molecules were estimated by subtracting the
number of minigene transcripts, estimated by quantitative PCR
with A/D primers (E22-F & E22-R) to the number of E24 copies,
estimated by quantitative PCR E/F primers (E24-F2 & E24-R2):
ExCh copy number=(E/F)2(A/D). mRNA levels were measured
by absolute quantitative real-time RT-PCR methods as described
previously using pCRA ˆH2.1-TOPOA ˆH-E22-E23-E24 as reference
sample and primers E22-F, E22-R CCGAGTCTCTCCTCCAT-
TATTTC, E24-F2 CACATAAAAACCTTACAGAAATG and
E24-R2 CTGCATTGTTTGAGCTGTTTTTTC. (A) Effect of
intronic splice enhancer sequences on exon replacement efficiency.
RT-PCR analysis using primers A and C of NIH3T3 cells
cotransfected with dystrophin minigene and constructs pSMD2
(Ctrl), pSMD2-U7-SD23-BP22 (U7) and the following ExCh
plasmids with AS4 or AS8: pSMD2-AS2-E24-AS’ (2), pSMD2-
AS2-ISE-E24-AS’ (ISE), pSMD2-AS2-E24-DISE-AS’ (DISE) and
pSMD2-AS2-E24-2XAS’ (2XAS’). H20: PCR negative control.
Histogram shows the number of ExCh molecules expressed for
100 copies of dystrophin minigene transcripts. DISE and 2XAS4
constructs are the most efficient (lanes 8 and 9). Accordingly to the
results obtained with AS2-E24-AS8 (lanes 10–13), it is clear that
highest efficacy of DISE and 2XAS4 did not resulted from
transcriptional over activity of these constructs. (B) Dosing study of
AS2-E24-DISE-AS4 molecule. RT-PCR analysis using primers A
and C of NIH3T3 cells cotransfected with 250 ng of dystrophin
minigene and 100, 200, 400 and 750 ng (lanes 2–5) of pSMD2-
AS2-E24-DISE-AS4 plasmids. Histogram shows the number of
ExCh molecules expressed for 100 copies of dystrophin minigene
transcripts and confirms that ExChange efficacy increases
accordingly to the amounts of AS2-E24-DISE-AS4 molecules.
Found at: doi:10.1371/journal.pone.0010894.s002 (3.66 MB
TIF)
Figure S3 Restriction analysis of clones containing E22-E23-
E24 inserts. The 507bp PCR-product obtained in samples
transfected with AS2-E23-DISE-AS4 plasmid (Fig. 6C) was cloned
into pCRA ˆH-2.1-TOPOA ˆH plasmid. Thirty clones were obtained
which were analyzed by EcoRI restriction for the presence of E22-
E23-E24 insert and by HindIII restriction to substantiate the
repaired amplicon. Among these 30 clones, 21 contained an E22-
E23-E24 insert (discernible by *). Among them, 5 displayed the
HindIII site (*), the feature of the repaired dystrophin minigene
product. Wild type exon 23 exchange in these clones was
confirmed by direct sequencing.
Found at: doi:10.1371/journal.pone.0010894.s003 (9.64 MB TIF)
Figure S4 Control experiments to exclude contribution of
plasmid recombination. In order to show that the repair occurred
at mRNA level by double trans-splicing and not by plasmid
recombination, two independent mutations were included in the
pSMD2-AS2-E24-DISE-AS4 construct. First, the CMV promoter
was deleted to prevent expression of the AS2-E24-DISE-AS4
ExCh molecule, pSMD2-AS2-E24-DISE-AS4-delCMV. Second,
the 59 splice site GT of the AS2-E24-DISE-AS4 molecule was
mutated to CT to create the splicing-deficient ExChange molecule
AS2-E24-DISE-AS4-del59SS. Absence of significant plasmid
recombination was also checked after DNA recovery from
cotransfected cells with dystrophin minigene and pSMD2-AS2-
E24-DISE-AS4 (DNA). After RT-PCR with primers A and C (see
Fig. 2B), no 408bp band corresponding to the repaired minigene
product was detected in the three conditions (lanes 3–5, delCMV,
del59SS and DNA), thus confirming that previously documented
ExChange (lane 2) did not occur at the level of plasmid
recombination and required a fully functional ExChange
molecule.
Found at: doi:10.1371/journal.pone.0010894.s004 (5.77 MB TIF)
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